Arteris, Inc.

Chief Financial Officer Departure:

As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2026, Nick Hawkins, the Company’s Chief Financial Officer, notified the Company of his intention to retire from his current executive position due to an illness in his family. Mr. Hawkins’ retirement will become effective September 7, 2026 (the Employment Departure Date).

The Company entered into a Separation and Consulting Agreement (the Separation Agreement) with Mr. Hawkins on July 31, 2026. Pursuant to the terms of the Separation Agreement, subject to Mr. Hawkins’ timely executing and not revoking a release of all claims against the Company, Mr. Hawkins’ continued employment through the Employment Departure Date or termination by the Company without Cause (as defined in the Separation Agreement) prior to the Employment Departure Date, and Mr. Hawkins’ compliance with the Continuing Obligations (as defined in the Separation Agreement), the Company will directly pay or reimburse Mr. Hawkins for the Company’s portion of COBRA premium payments for Mr. Hawkins and his covered dependents for eighteen (18) months, or until Mr. Hawkins becomes eligible for coverage under another employer's health plan, whichever occurs earlier.

Pursuant to the Separation Agreement, beginning the Employment Departure Date, and ending on August 31, 2027 (the Consulting Period), Mr. Hawkins will serve as a transitional advisor to the Company and, subject to his timely execution and non-revocation of a second general release of all claims against the Company on or following August 31, 2027, and Mr. Hawkins’ compliance during the Consulting Period with certain restrictive covenants, each of Mr. Hawkins' then-outstanding and unvested restricted stock units and stock options subject to a time-based vesting schedule (the Hawkins Awards) will be amended such that those awards will continue to vest during the Consulting Period at a rate equal to fifty percent (50%) of the rate at which each such award would have otherwise vested pursuant to the original vesting schedule, subject to Mr. Hawkins' continuous service through each applicable vesting date. In addition, the Company will pay reasonable legal fees of up to $10,000 incurred by Mr. Hawkins in negotiating the Separation Agreement.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated by reference herein.

10b5-1 plans:

On May 20, 2026, Wayne Cantwell, Director, as the trustee of the Cantwell Living Trust, adopted a Rule 10b5-1 trading arrangement of the Cantwell Living Trust that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 78,198 shares of the Company’s common stock until May 31, 2027.

On May 27, 2026, Raman Chitkara, Director, adopted a Rule 10b5-1 trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,000 shares of the Company’s common stock until June 30, 2027.

On June 9, 2026, Antonio Viana, Director, as the trustee of the Viana Family Trust, terminated a Rule 10b5-1 trading arrangement of the Viana Family Trust that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 219,589 shares of the Company’s common stock until September 30, 2026.

On June 15, 2026, Laurent Moll, Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 122,043 shares of the Company’s common stock until June 30, 2027.